Syros Pharmaceuticals Inc... (SYRS)
| Bid | n/a |
| Market Cap | 638.61K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.07 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | -0.06 |
| Analyst | Hold |
| Ask | n/a |
| Volume | 130,863 |
| Avg. Volume (20D) | 25,513,269 |
| Open | 0.02 |
| Previous Close | 0.02 |
| Day's Range | 0.01 - 0.02 |
| 52-Week Range | 0.01 - 6.93 |
| Beta | 1.88 |
About SYRS
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acu...
Analyst Forecast
According to 5 analyst ratings, the average rating for SYRS stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 12505.04% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
Syros Announces Voluntary Delisting from Nasdaq and SEC DeregistrationCAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed w...